Back

Eukaryotic Initiation Factor 5B (eIF5B)-Driven Translational Control Impacts Oral Squamous Cell Carcinoma Pathophysiology

Lakshmi Narasimha, P.; Patel, J.; Chanda, A.; Hegde, V.; Fernando, B. H.; Stephenson, H.; Mubaya, R.; Shrestha, A.; Nakoneshny, S. C.; Ahn, B. Y.; Matthews, T. W.; Chandarana, S.; Hart, R.; Dort, J. C.; Hyrcza, M.; Todorovic, E.; Jafarnejad, S. M.; Bose, P.; Thakor, N.

2026-02-02 cancer biology
10.64898/2026.01.30.702967 bioRxiv
Show abstract

The non-canonical translation of specific mRNAs has been implicated in oncogenesis and cancer progression. We previously identified eukaryotic Initiation Factor 5B (eIF5B) as a key factor in Internal Ribosome Entry Site (IRES)-mediated translation of a subset of mRNAs encoding anti-apoptotic proteins. Here, we demonstrate that EIF5B is predominantly expressed in cancer cells compared to other cell types in the Oral Squamous Cell Carcinoma (OSCC) microenvironment. Higher EIF5B mRNA and protein expression are associated with poor patient outcomes. We show that eIF5B depletion in OSCC cells blunted pro-growth, pro-inflammatory, and pro-angiogenic signaling pathways and significantly increased TNF-related apoptosis-inducing ligand (TRAIL)-induced cell death. This is achieved through decreased translation of mRNAs encoding critical factors associated with OSCC pathophysiology. Importantly, the level of interaction of eIF5B with tRNAiMet was significantly higher in OSCC cells compared to non-cancerous fibroblasts. This suggests that OSCC cells (but not non-cancerous fibroblasts) rely heavily on eIF5B for translation initiation. In an in vivo flank xenograft model using nude mice, eIF5B knockdown in UMSCC-29 cells led to a significant reduction in tumor volume compared to control tumors. Also, the immunohistochemical analysis of the xenografted tumor sections demonstrated decreased staining intensity of critical factors associated with OSCC pathophysiology in eIF5B-depleted tumors relative to controls. Collectively, our data demonstrate that OSCC cells are uniquely dependent on eIF5B-tRNA interactions to sustain translation of pro-survival mRNAs. Targeting eIF5B disrupts these oncogenic programs, sensitizing OSCC cells to apoptosis and suppressing pro-angiogenic and pro-growth signaling.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Oncogene
76 papers in training set
Top 0.1%
33.0%
2
Molecular Cancer Research
42 papers in training set
Top 0.1%
4.9%
3
Cancer Research
116 papers in training set
Top 0.5%
4.3%
4
Cell Reports
1338 papers in training set
Top 12%
4.2%
5
Cancers
200 papers in training set
Top 2%
3.7%
50% of probability mass above
6
Cell Death & Disease
126 papers in training set
Top 0.3%
3.7%
7
Cancer Research Communications
46 papers in training set
Top 0.1%
3.6%
8
eLife
5422 papers in training set
Top 36%
2.1%
9
Molecular Cancer Therapeutics
33 papers in training set
Top 0.3%
2.1%
10
JCI Insight
241 papers in training set
Top 3%
1.9%
11
Journal of Clinical Investigation
164 papers in training set
Top 3%
1.8%
12
Cancer Letters
32 papers in training set
Top 0.2%
1.7%
13
Molecular Oncology
50 papers in training set
Top 0.4%
1.7%
14
Journal of Biological Chemistry
641 papers in training set
Top 2%
1.5%
15
Scientific Reports
3102 papers in training set
Top 64%
1.3%
16
BMC Cancer
52 papers in training set
Top 2%
1.2%
17
Nature Communications
4913 papers in training set
Top 56%
1.2%
18
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.0%
19
NAR Cancer
36 papers in training set
Top 0.1%
1.0%
20
PLOS ONE
4510 papers in training set
Top 63%
1.0%
21
International Journal of Cancer
42 papers in training set
Top 1%
0.9%
22
Communications Biology
886 papers in training set
Top 21%
0.8%
23
mBio
750 papers in training set
Top 11%
0.8%
24
British Journal of Cancer
42 papers in training set
Top 2%
0.7%
25
Advanced Science
249 papers in training set
Top 19%
0.7%
26
Molecular Cancer
14 papers in training set
Top 1.0%
0.7%
27
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 44%
0.7%
28
Clinical Cancer Research
58 papers in training set
Top 2%
0.7%
29
Molecular Biology of the Cell
272 papers in training set
Top 3%
0.7%
30
Oncogenesis
12 papers in training set
Top 0.2%
0.7%